VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q42966101 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241221010839.0
008 241221nneanz||abbn n and d
035 ‎‡a (WKP)Q42966101‏
024 ‎‡a 0000-0002-5695-348X‏ ‎‡2 orcid‏
024 ‎‡a 16242700100‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q42966101‏
100 0 ‎‡a Manuel Sánchez de la Torre‏ ‎‡9 ast‏ ‎‡9 es‏ ‎‡9 sl‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Manuel Sánchez de la Torre‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Manuel Sánchez de la Torre‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's Acetylsalicylic Acid Prevents Intermittent Hypoxia-Induced Vascular Remodeling in a Murine Model of Sleep Apnea.‏
670 ‎‡a Author's Analysis of meiotic recombination in 22q11.2, a region that frequently undergoes deletions and duplications‏
670 ‎‡a Author's Assessing sleep health in a European population: Results of the Catalan Health Survey 2015.‏
670 ‎‡a Author's Association between Obstructive Sleep Apnea and Community-Acquired Pneumonia.‏
670 ‎‡a Author's Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea.‏
670 ‎‡a Author's Blood pressure improvement with continuous positive airway pressure is independent of obstructive sleep apnea severity‏
670 ‎‡a Author's Cancer and Sleep Apnea: Cutaneous Melanoma as a Case Study‏
670 ‎‡a Author's Characterization of the CPAP-treated patient population in Catalonia‏
670 ‎‡a Author's Comparative analysis of predictive methods for early assessment of compliance with continuous positive airway pressure therapy‏
670 ‎‡a Author's Corneal biomechanical properties in floppy eyelid syndrome.‏
670 ‎‡a Author's Day-night variations in endothelial dysfunction markers and haemostatic factors in sleep apnoea‏
670 ‎‡a Author's Effect of CPAP treatment on plasma high sensitivity troponin levels in patients with obstructive sleep apnea.‏
670 ‎‡a Author's Erectile dysfunction in obstructive sleep apnea patients: A randomized trial on the effects of Continuous Positive Airway Pressure‏
670 ‎‡a Author's Erectile dysfunction in obstructive sleep apnea patients: A randomized trial on the effects of Continuous Positive Airway Pressure (CPAP)‏
670 ‎‡a Author's Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnoea.‏
670 ‎‡a Author's GESAP trial rationale and methodology: management of patients with suspected obstructive sleep apnea in primary care units compared to sleep units‏
670 ‎‡a Author's Gut epithelial barrier markers in patients with obstructive sleep apnea.‏
670 ‎‡a Author's Identification and validation of circulating miRNAs as endogenous controls in obstructive sleep apnea‏
670 ‎‡a Author's Immunophenotype of vitamin D receptor polymorphism associated to risk of HIV-1 infection and rate of disease progression‏
670 ‎‡a Author's Impact of obstructive sleep apnea on the 24-h metabolic hormone profile.‏
670 ‎‡a Author's Impact of Obstructive Sleep Apnea on the Levels of Placental Growth Factor (PlGF) and Their Value for Predicting Short-Term Adverse Outcomes in Patients with Acute Coronary Syndrome‏
670 ‎‡a Author's Impact of OSA on biological markers in morbid obesity and metabolic syndrome‏
670 ‎‡a Author's Intermittent Hypoxia-Induced Cardiovascular Remodeling Is Reversed by Normoxia in a Mouse Model of Sleep Apnea.‏
670 ‎‡a Author's Intermittent Hypoxia Is Associated With High Hypoxia Inducible Factor-1α but Not High Vascular Endothelial Growth Factor Cell Expression in Tumors of Cutaneous Melanoma Patients.‏
670 ‎‡a Author's Long-term adherence to continuous positive airway pressure therapy in non-sleepy sleep apnea patients.‏
670 ‎‡a Author's Management of continuous positive airway pressure treatment compliance using telemonitoring in obstructive sleep apnoea.‏
670 ‎‡a Author's Management of obstructive sleep apnoea in a primary care vs sleep unit setting: a randomised controlled trial‏
670 ‎‡a Author's Metabolic syndrome, insulin resistance and sleepiness in real-life obstructive sleep apnoea‏
670 ‎‡a Author's Mortality in Patients Treated with Continuous Positive Airway Pressure at the Population Level‏
670 ‎‡a Author's NADPH oxidase p22phox polymorphisms and oxidative stress in patients with obstructive sleep apnoea.‏
670 ‎‡a Author's Non-synonymous polymorphism in the neuropeptide S precursor gene and sleep apnea.‏
670 ‎‡a Author's Normotensive patients with obstructive sleep apnoea: changes in 24-h ambulatory blood pressure monitoring with continuous positive airway pressure treatment‏
670 ‎‡a Author's Obstructive sleep apnea: in search of precision‏
670 ‎‡a Author's Obstructive sleep apnoea and cardiovascular disease‏
670 ‎‡a Author's Personalized medicine in sleep apnea: Towards a new paradigm of comprehensive disease management‏
670 ‎‡a Author's Plasma levels of neuropeptides and metabolic hormones, and sleepiness in obstructive sleep apnea.‏
670 ‎‡a Author's Precision medicine: A modern odyssey‏
670 ‎‡a Author's Prevalence, Characteristics, and Association of Obstructive Sleep Apnea with Blood Pressure Control in Patients with Resistant Hypertension‏
670 ‎‡a Author's Rationale and methodology of the impact of continuous positive airway pressure on patients with ACS and nonsleepy OSA: the ISAACC Trial.‏
670 ‎‡a Author's Rationale and Methodology of the SARAH Trial: Long-Term Cardiovascular Outcomes in Patients With Resistant Hypertension and Obstructive Sleep Apnea‏
670 ‎‡a Author's Reply: Precision Medicine, Obstructive Sleep Apnea, and Refractory Hypertension‏
670 ‎‡a Author's Reply: To PMID 25747162.‏
670 ‎‡a Author's Respiratory Disorders During Sleep: A New Dimension for 2018‏
670 ‎‡a Author's Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients‏
670 ‎‡a Author's Subcutaneous advanced glycation end-products and lung function according to glucose abnormalities: The ILERVAS Project.‏
670 ‎‡a Author's Tagging long-lived individuals through vitamin-D receptor‏
670 ‎‡a Author's Tagging long-lived individuals through vitamin-D receptor (VDR) haplotypes‏
670 ‎‡a Author's The Effect of Sleep Apnea on Cardiovascular Events in Different Acute Coronary Syndrome Phenotypes‏
670 ‎‡a Author's The influence of obesity and obstructive sleep apnea on metabolic hormones‏
670 ‎‡a Author's The relationship between floppy eyelid syndrome and obstructive sleep apnoea.‏
670 ‎‡a Author's The Use of Precision Medicine to Manage Obstructive Sleep Apnea Treatment in Patients with Resistant Hypertension: Current Evidence and Future Directions‏
670 ‎‡a Author's Use of Ambulatory Blood Pressure Monitoring for the Screening of Obstructive Sleep Apnea‏
670 ‎‡a Author's Vitamin-D pathway genes and HIV-1 disease progression in injection drug users‏
670 ‎‡a Author's Vitamin D status and parathyroid hormone levels in patients with obstructive sleep apnea‏
670 ‎‡a Author's What treatment wins in the battle against sleepiness?‏
909 ‎‡a (orcid) 000000025695348x‏ ‎‡9 1‏
909 ‎‡a (scopus) 16242700100‏ ‎‡9 1‏
919 ‎‡a analysisofmeioticrecombinationin22q112aregionthatfrequentlyundergoesdeletionsandduplications‏ ‎‡A Analysis of meiotic recombination in 22q11.2, a region that frequently undergoes deletions and duplications‏ ‎‡9 1‏
919 ‎‡a assessingsleephealthinaeuropeanpopulationresultsofthecatalanhealthsurvey‏ ‎‡A Assessing sleep health in a European population: Results of the Catalan Health Survey 2015.‏ ‎‡9 1‏
919 ‎‡a associationbetweenobstructivesleepapneaandcommunityacquiredpneumonia‏ ‎‡A Association between Obstructive Sleep Apnea and Community-Acquired Pneumonia.‏ ‎‡9 1‏
919 ‎‡a biomarkersofcarcinogenesisandtumourgrowthinpatientswithcutaneousmelanomaandobstructivesleepapnoea‏ ‎‡A Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea.‏ ‎‡9 1‏
919 ‎‡a bloodpressureimprovementwithcontinuouspositiveairwaypressureisindependentofobstructivesleepapneaseverity‏ ‎‡A Blood pressure improvement with continuous positive airway pressure is independent of obstructive sleep apnea severity‏ ‎‡9 1‏
919 ‎‡a cancerandsleepapneacutaneousmelanomaasacasestudy‏ ‎‡A Cancer and Sleep Apnea: Cutaneous Melanoma as a Case Study‏ ‎‡9 1‏
919 ‎‡a characterizationofthecpaptreatedpatientpopulationincatalonia‏ ‎‡A Characterization of the CPAP-treated patient population in Catalonia‏ ‎‡9 1‏
919 ‎‡a comparativeanalysisofpredictivemethodsforearlyassessmentofcompliancewithcontinuouspositiveairwaypressuretherapy‏ ‎‡A Comparative analysis of predictive methods for early assessment of compliance with continuous positive airway pressure therapy‏ ‎‡9 1‏
919 ‎‡a cornealbiomechanicalpropertiesinfloppyeyelidsyndrome‏ ‎‡A Corneal biomechanical properties in floppy eyelid syndrome.‏ ‎‡9 1‏
919 ‎‡a daynightvariationsinendothelialdysfunctionmarkersandhaemostaticfactorsinsleepapnoea‏ ‎‡A Day-night variations in endothelial dysfunction markers and haemostatic factors in sleep apnoea‏ ‎‡9 1‏
919 ‎‡a effectofcpaptreatmentonplasmahighsensitivitytroponinlevelsinpatientswithobstructivesleepapnea‏ ‎‡A Effect of CPAP treatment on plasma high sensitivity troponin levels in patients with obstructive sleep apnea.‏ ‎‡9 1‏
919 ‎‡a erectiledysfunctioninobstructivesleepapneapatientsarandomizedtrialontheeffectsofcontinuouspositiveairwaypressure‏ ‎‡A Erectile dysfunction in obstructive sleep apnea patients: A randomized trial on the effects of Continuous Positive Airway Pressure‏ ‎‡9 1‏
919 ‎‡a erectiledysfunctioninobstructivesleepapneapatientsarandomizedtrialontheeffectsofcontinuouspositiveairwaypressurecpap‏ ‎‡A Erectile dysfunction in obstructive sleep apnea patients: A randomized trial on the effects of Continuous Positive Airway Pressure (CPAP)‏ ‎‡9 1‏
919 ‎‡a freefattyacidsandthemetabolicsyndromeinpatientswithobstructivesleepapnoea‏ ‎‡A Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnoea.‏ ‎‡9 1‏
919 ‎‡a gesaptrialrationaleandmethodologymanagementofpatientswithsuspectedobstructivesleepapneainprimarycareunitscomparedtosleepunits‏ ‎‡A GESAP trial rationale and methodology: management of patients with suspected obstructive sleep apnea in primary care units compared to sleep units‏ ‎‡9 1‏
919 ‎‡a gutepithelialbarriermarkersinpatientswithobstructivesleepapnea‏ ‎‡A Gut epithelial barrier markers in patients with obstructive sleep apnea.‏ ‎‡9 1‏
919 ‎‡a identificationandvalidationofcirculatingmirnasasendogenouscontrolsinobstructivesleepapnea‏ ‎‡A Identification and validation of circulating miRNAs as endogenous controls in obstructive sleep apnea‏ ‎‡9 1‏
919 ‎‡a immunophenotypeofvitamin500receptorpolymorphismassociatedtoriskofhiv1infectionandrateofdiseaseprogression‏ ‎‡A Immunophenotype of vitamin D receptor polymorphism associated to risk of HIV-1 infection and rate of disease progression‏ ‎‡9 1‏
919 ‎‡a impactofobstructivesleepapneaonthe24hmetabolichormoneprofile‏ ‎‡A Impact of obstructive sleep apnea on the 24-h metabolic hormone profile.‏ ‎‡9 1‏
919 ‎‡a impactofobstructivesleepapneaonthelevelsofplacentalgrowthfactorplgfandtheirvalueforpredictingshorttermadverseoutcomesinpatientswithacutecoronarysyndrome‏ ‎‡A Impact of Obstructive Sleep Apnea on the Levels of Placental Growth Factor (PlGF) and Their Value for Predicting Short-Term Adverse Outcomes in Patients with Acute Coronary Syndrome‏ ‎‡9 1‏
919 ‎‡a impactofosaonbiologicalmarkersinmorbidobesityandmetabolicsyndrome‏ ‎‡A Impact of OSA on biological markers in morbid obesity and metabolic syndrome‏ ‎‡9 1‏
919 ‎‡a intermittenthypoxiainducedcardiovascularremodelingisreversedbynormoxiainamousemodelofsleepapnea‏ ‎‡A Intermittent Hypoxia-Induced Cardiovascular Remodeling Is Reversed by Normoxia in a Mouse Model of Sleep Apnea.‏ ‎‡9 1‏
919 ‎‡a intermittenthypoxiaisassociatedwithhighhypoxiainduciblefactor1αbutnothighvascularendothelialgrowthfactorcellexpressionintumorsofcutaneousmelanomapatients‏ ‎‡A Intermittent Hypoxia Is Associated With High Hypoxia Inducible Factor-1α but Not High Vascular Endothelial Growth Factor Cell Expression in Tumors of Cutaneous Melanoma Patients.‏ ‎‡9 1‏
919 ‎‡a longtermadherencetocontinuouspositiveairwaypressuretherapyinnonsleepysleepapneapatients‏ ‎‡A Long-term adherence to continuous positive airway pressure therapy in non-sleepy sleep apnea patients.‏ ‎‡9 1‏
919 ‎‡a managementofcontinuouspositiveairwaypressuretreatmentcomplianceusingtelemonitoringinobstructivesleepapnoea‏ ‎‡A Management of continuous positive airway pressure treatment compliance using telemonitoring in obstructive sleep apnoea.‏ ‎‡9 1‏
919 ‎‡a managementofobstructivesleepapnoeainaprimarycarevssleepunitsettingarandomisedcontrolledtrial‏ ‎‡A Management of obstructive sleep apnoea in a primary care vs sleep unit setting: a randomised controlled trial‏ ‎‡9 1‏
919 ‎‡a metabolicsyndromeinsulinresistanceandsleepinessinreallifeobstructivesleepapnoea‏ ‎‡A Metabolic syndrome, insulin resistance and sleepiness in real-life obstructive sleep apnoea‏ ‎‡9 1‏
919 ‎‡a mortalityinpatientstreatedwithcontinuouspositiveairwaypressureatthepopulationlevel‏ ‎‡A Mortality in Patients Treated with Continuous Positive Airway Pressure at the Population Level‏ ‎‡9 1‏
919 ‎‡a nadphoxidasep22phoxpolymorphismsandoxidativestressinpatientswithobstructivesleepapnoea‏ ‎‡A NADPH oxidase p22phox polymorphisms and oxidative stress in patients with obstructive sleep apnoea.‏ ‎‡9 1‏
919 ‎‡a nonsynonymouspolymorphismintheneuropeptidesprecursorgeneandsleepapnea‏ ‎‡A Non-synonymous polymorphism in the neuropeptide S precursor gene and sleep apnea.‏ ‎‡9 1‏
919 ‎‡a normotensivepatientswithobstructivesleepapnoeachangesin24hambulatorybloodpressuremonitoringwithcontinuouspositiveairwaypressuretreatment‏ ‎‡A Normotensive patients with obstructive sleep apnoea: changes in 24-h ambulatory blood pressure monitoring with continuous positive airway pressure treatment‏ ‎‡9 1‏
919 ‎‡a obstructivesleepapneainsearchofprecision‏ ‎‡A Obstructive sleep apnea: in search of precision‏ ‎‡9 1‏
919 ‎‡a obstructivesleepapnoeaandcardiovasculardisease‏ ‎‡A Obstructive sleep apnoea and cardiovascular disease‏ ‎‡9 1‏
919 ‎‡a personalizedmedicineinsleepapneatowardsanewparadigmofcomprehensivediseasemanagement‏ ‎‡A Personalized medicine in sleep apnea: Towards a new paradigm of comprehensive disease management‏ ‎‡9 1‏
919 ‎‡a plasmalevelsofneuropeptidesandmetabolichormonesandsleepinessinobstructivesleepapnea‏ ‎‡A Plasma levels of neuropeptides and metabolic hormones, and sleepiness in obstructive sleep apnea.‏ ‎‡9 1‏
919 ‎‡a precisionmedicineamodernodyssey‏ ‎‡A Precision medicine: A modern odyssey‏ ‎‡9 1‏
919 ‎‡a prevalencecharacteristicsandassociationofobstructivesleepapneawithbloodpressurecontrolinpatientswithresistanthypertension‏ ‎‡A Prevalence, Characteristics, and Association of Obstructive Sleep Apnea with Blood Pressure Control in Patients with Resistant Hypertension‏ ‎‡9 1‏
919 ‎‡a rationaleandmethodologyoftheimpactofcontinuouspositiveairwaypressureonpatientswithacsandnonsleepyosatheisaacctrial‏ ‎‡A Rationale and methodology of the impact of continuous positive airway pressure on patients with ACS and nonsleepy OSA: the ISAACC Trial.‏ ‎‡9 1‏
919 ‎‡a rationaleandmethodologyofthesarahtriallongtermcardiovascularoutcomesinpatientswithresistanthypertensionandobstructivesleepapnea‏ ‎‡A Rationale and Methodology of the SARAH Trial: Long-Term Cardiovascular Outcomes in Patients With Resistant Hypertension and Obstructive Sleep Apnea‏ ‎‡9 1‏
919 ‎‡a replyprecisionmedicineobstructivesleepapneaandrefractoryhypertension‏ ‎‡A Reply: Precision Medicine, Obstructive Sleep Apnea, and Refractory Hypertension‏ ‎‡9 1‏
919 ‎‡a replytopmid25747162‏ ‎‡A Reply: To PMID 25747162.‏ ‎‡9 1‏
919 ‎‡a respiratorydisordersduringsleepanewdimensionfor‏ ‎‡A Respiratory Disorders During Sleep: A New Dimension for 2018‏ ‎‡9 1‏
919 ‎‡a solublepdl1isapotentialbiomarkerofcutaneousmelanomaaggressivenessandmetastasisinobstructivesleepapnoeapatients‏ ‎‡A Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients‏ ‎‡9 1‏
919 ‎‡a subcutaneousadvancedglycationendproductsandlungfunctionaccordingtoglucoseabnormalitiestheilervasproject‏ ‎‡A Subcutaneous advanced glycation end-products and lung function according to glucose abnormalities: The ILERVAS Project.‏ ‎‡9 1‏
919 ‎‡a tagginglonglivedindividualsthroughvitamin500receptor‏ ‎‡A Tagging long-lived individuals through vitamin-D receptor‏ ‎‡9 1‏
919 ‎‡a tagginglonglivedindividualsthroughvitamin500receptorvdrhaplotypes‏ ‎‡A Tagging long-lived individuals through vitamin-D receptor (VDR) haplotypes‏ ‎‡9 1‏
919 ‎‡a effectofsleepapneaoncardiovasculareventsindifferentacutecoronarysyndromephenotypes‏ ‎‡A The Effect of Sleep Apnea on Cardiovascular Events in Different Acute Coronary Syndrome Phenotypes‏ ‎‡9 1‏
919 ‎‡a influenceofobesityandobstructivesleepapneaonmetabolichormones‏ ‎‡A The influence of obesity and obstructive sleep apnea on metabolic hormones‏ ‎‡9 1‏
919 ‎‡a relationshipbetweenfloppyeyelidsyndromeandobstructivesleepapnoea‏ ‎‡A The relationship between floppy eyelid syndrome and obstructive sleep apnoea.‏ ‎‡9 1‏
919 ‎‡a useofprecisionmedicinetomanageobstructivesleepapneatreatmentinpatientswithresistanthypertensioncurrentevidenceandfuturedirections‏ ‎‡A The Use of Precision Medicine to Manage Obstructive Sleep Apnea Treatment in Patients with Resistant Hypertension: Current Evidence and Future Directions‏ ‎‡9 1‏
919 ‎‡a useofambulatorybloodpressuremonitoringforthescreeningofobstructivesleepapnea‏ ‎‡A Use of Ambulatory Blood Pressure Monitoring for the Screening of Obstructive Sleep Apnea‏ ‎‡9 1‏
919 ‎‡a vitamin500pathwaygenesandhiv1diseaseprogressionininjectiondrugusers‏ ‎‡A Vitamin-D pathway genes and HIV-1 disease progression in injection drug users‏ ‎‡9 1‏
919 ‎‡a vitamin500statusandparathyroidhormonelevelsinpatientswithobstructivesleepapnea‏ ‎‡A Vitamin D status and parathyroid hormone levels in patients with obstructive sleep apnea‏ ‎‡9 1‏
919 ‎‡a whattreatmentwinsinthebattleagainstsleepiness‏ ‎‡A What treatment wins in the battle against sleepiness?‏ ‎‡9 1‏
919 ‎‡a acetylsalicylicacidpreventsintermittenthypoxiainducedvascularremodelinginamurinemodelofsleepapnea‏ ‎‡A Acetylsalicylic Acid Prevents Intermittent Hypoxia-Induced Vascular Remodeling in a Murine Model of Sleep Apnea.‏ ‎‡9 1‏
943 ‎‡a 201x‏ ‎‡A 2018‏ ‎‡9 2‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 DNB|1056681551‏
996 ‎‡2 BNE|XX5055969‏
996 ‎‡2 BNE|XX1439044‏
996 ‎‡2 BNC|981058515141006706‏
996 ‎‡2 LC|no2014158455‏
996 ‎‡2 BNE|XX969781‏
996 ‎‡2 BNE|XX1075477‏
996 ‎‡2 BNE|XX931066‏
996 ‎‡2 LC|no2006087533‏
996 ‎‡2 SUDOC|242752934‏
996 ‎‡2 ISNI|0000000059569518‏
996 ‎‡2 LC|no 91018758‏
996 ‎‡2 LC|no2015114582‏
996 ‎‡2 BNC|981058522364806706‏
996 ‎‡2 J9U|987009349374305171‏
996 ‎‡2 LC|n 91036848‏
996 ‎‡2 ISNI|0000000053278437‏
996 ‎‡2 ICCU|BVEV254014‏
996 ‎‡2 SUDOC|243355629‏
996 ‎‡2 ISNI|0000000043243345‏
996 ‎‡2 ISNI|0000000123627912‏
996 ‎‡2 ISNI|0000000069408937‏
996 ‎‡2 ISNI|0000000116074782‏
996 ‎‡2 DNB|118977946‏
996 ‎‡2 SUDOC|203396510‏
996 ‎‡2 DNB|1146362765‏
996 ‎‡2 J9U|987007363975605171‏
996 ‎‡2 NUKAT|n 2006095840‏
996 ‎‡2 BNE|XX1274016‏
996 ‎‡2 NUKAT|n 2021090383‏
996 ‎‡2 ISNI|0000000062882716‏
996 ‎‡2 ISNI|0000000059647053‏
996 ‎‡2 ISNI|0000000048847930‏
996 ‎‡2 LC|n 2008039908‏
996 ‎‡2 LC|no2005064592‏
996 ‎‡2 ISNI|0000000388764402‏
996 ‎‡2 DNB|1158863500‏
996 ‎‡2 J9U|987007363767905171‏
996 ‎‡2 ISNI|0000000028192316‏
996 ‎‡2 ISNI|0000000061393902‏
996 ‎‡2 DNB|1053300468‏
996 ‎‡2 BNC|981058618234106706‏
996 ‎‡2 ISNI|0000000060610207‏
996 ‎‡2 BNF|17807648‏
996 ‎‡2 BNE|XX823632‏
996 ‎‡2 ISNI|0000000048149905‏
996 ‎‡2 NUKAT|n 2018092258‏
996 ‎‡2 BNE|XX1551567‏
996 ‎‡2 LC|n 92010262‏
996 ‎‡2 RERO|A021686211‏
996 ‎‡2 NSK|000187720‏
996 ‎‡2 BNE|XX1098870‏
996 ‎‡2 LC|n 2020068162‏
996 ‎‡2 ISNI|0000000425396830‏
996 ‎‡2 LC|ns2019004001‏
996 ‎‡2 BNC|981058610254606706‏
996 ‎‡2 BNE|XX1746992‏
996 ‎‡2 BLBNB|000538060‏
996 ‎‡2 BNE|XX4946436‏
996 ‎‡2 LC|no2024010997‏
996 ‎‡2 LC|no2017012748‏
996 ‎‡2 BNF|16526901‏
996 ‎‡2 ISNI|0000000040997408‏
996 ‎‡2 PTBNP|195311‏
996 ‎‡2 BNE|XX6399734‏
996 ‎‡2 CAOONL|ncf13690436‏
996 ‎‡2 DNB|1287160689‏
996 ‎‡2 ISNI|0000000039801180‏
996 ‎‡2 BNCHL|10000000000000000066101‏
996 ‎‡2 LC|n 92020967‏
996 ‎‡2 BNCHL|10000000000000000275508‏
996 ‎‡2 BNC|981058596007306706‏
996 ‎‡2 BNC|981058515709306706‏
996 ‎‡2 DNB|1067814655‏
996 ‎‡2 BNE|XX1066332‏
996 ‎‡2 LC|nr2001038964‏
996 ‎‡2 BNE|XX873548‏
996 ‎‡2 BNE|XX6056678‏
996 ‎‡2 LC|n 2001040891‏
996 ‎‡2 BNF|13959448‏
996 ‎‡2 PTBNP|230951‏
996 ‎‡2 SUDOC|264725387‏
996 ‎‡2 ISNI|0000000417228407‏
996 ‎‡2 ISNI|0000000355178589‏
996 ‎‡2 BNE|XX1336496‏
996 ‎‡2 SUDOC|26180748X‏
996 ‎‡2 NII|DA08781482‏
996 ‎‡2 LC|nb2008007429‏
996 ‎‡2 LC|no2004057138‏
996 ‎‡2 NTA|145732002‏
996 ‎‡2 ISNI|0000000070827581‏
996 ‎‡2 SZ|118977946‏
996 ‎‡2 SUDOC|220059551‏
996 ‎‡2 BNC|981058515708706706‏
996 ‎‡2 SUDOC|142989037‏
996 ‎‡2 SUDOC|257093982‏
996 ‎‡2 BNCHL|10000000000000000223933‏
996 ‎‡2 ISNI|000000011650771X‏
996 ‎‡2 LC|n 85129114‏
996 ‎‡2 ISNI|0000000034396438‏
996 ‎‡2 LC|n 88025632‏
996 ‎‡2 BNE|XX1100691‏
996 ‎‡2 BNE|XX1672813‏
996 ‎‡2 CAOONL|ncf11638036‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏